Innate Pharma doses first patient in Nectin-4 ADC trial
The Phase I trial will evaluate the safety and efficacy of the company’s drug which targets tumours whilst leaving normal ...
Suven Pharma looks for 6x increase in revenue by FY35
Looking to the future, Suven’s Horizon 2 initiative – which includes plans to incorporate capabilities in flow chemistry, ...
Hosted on MSN13h
Astellas Exec Talks Dealmaking and Pipeline Strategy in Cancer, Gene Therapy & More
The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer ...
manilatimes14h
Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA
Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...